Reproxalap

Aldeyra Therapeutics announced the FDA accepted its resubmitted NDA for topical ocular reproxalap, targeting dry eye disease, with a PDUFA date of April 2, 2025. The company also expanded its option agreement with AbbVie, which could lead to a $100 million upfront payment and up to $300 million in milestone payments.

Aldeyra Therapeutics announced FDA's acceptance of the resubmitted NDA for reproxalap, targeting dry eye disease, with a PDUFA date of April 2, 2025. The company also expanded its option agreement with AbbVie, involving a $100 million upfront payment and up to $300 million in milestone payments, sharing profits 60/40. Reproxalap, a RASP modulator, has shown promise in treating dry eye disease and allergic conjunctivitis without significant safety concerns.

Aldeyra Therapeutics' NDA for reproxalap, a novel dry eye disease treatment, accepted by FDA with a PDUFA date of April 2, 2025. Expanded option agreement with AbbVie includes a $100M upfront payment and up to $300M in milestone payments, with a 60/40 profit split post-approval.

Aldeyra Therapeutics' NDA for reproxalap, a dry eye disease treatment, accepted by FDA with a PDUFA date of April 2, 2025. Expanded agreement with AbbVie includes pre-commercial activities, cost-sharing, and potential $300M in milestone payments, highlighting commitment to therapy availability.

Aldeyra Therapeutics' NDA for reproxalap, a dry eye disease treatment, was accepted by the FDA, with a review date set for April 2, 2025. The company expanded its option agreement with AbbVie, potentially leading to a $100 million upfront payment and up to $300 million in milestone payments, sharing profits 60/40.

Aldeyra Therapeutics' NDA for reproxalap, a dry eye disease treatment, is under FDA review with a PDUFA date of April 2, 2025. A partnership with AbbVie could yield Aldeyra up to $400 million, including a $100 million payment upon FDA approval. Reproxalap targets RASP, showing promise in clinical trials. Aldeyra also advances other RASP modulators for various diseases.

Aldeyra Therapeutics' NDA for reproxalap, a dry eye disease treatment, was accepted by the FDA, with a PDUFA date of April 2, 2025. The company expanded its option agreement with AbbVie, which could lead to a $100M upfront payment and up to $300M in milestone payments, sharing profits 60/40. Pre-commercial activities will be jointly funded.

Aldeyra Therapeutics' FDA-accepted NDA resubmission for reproxalap targets dry eye disease, with a decision expected by April 2, 2025. Following a 2023 CRL, a phase III study met primary endpoints, leading to the resubmission. Aldeyra also expanded its option agreement with AbbVie, sharing pre-commercial costs. Shares rose 11.6% post-announcement.

Aldeyra Therapeutics resubmitted a new drug application for reproxalap, aiming to treat dry eye disease. Reproxalap could be the first chronic-use therapy for dry eye, showing potential in reducing symptoms and ocular redness. The resubmission includes positive trial results and a draft label highlighting acute and chronic improvements.

American Century Companies Inc. increased its holdings in Aldeyra Therapeutics by 216.7% in Q2. Several other institutional investors also adjusted their positions. HC Wainwright maintained a 'buy' rating with a $10.00 target price. ALDX stock opened at $5.34 on Friday, with a market cap of $317.27 million.